Guardant Health is a company within the Biotechnology category. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. The company specializes in liquid biopsy technology to provide genomic insights across all stages of the cancer care continuum, from screening to therapy selection and recurrence monitoring.
Guardant Health was founded in 2012 and is headquartered in Palo Alto, CA.
Guardant Health is part of Independent Publicly Traded.
Guardant Health is rated Leader on the Optimly Brand Authority Index, a measure of how well AI models can accurately describe the brand. The exact score is locked for unclaimed profiles.
AI narrative accuracy for Guardant Health is Moderate. Significant factual deltas detected. Inconsistent representation across models.
AI models classify Guardant Health as a Challenger. AI names competitors first.
Guardant Health appeared in 6 of 8 sampled buyer-intent queries (75%). Guardant Health has high visibility for brand-specific queries but faces competition from Natera and Foundation Medicine in unbranded queries related to liquid biopsy and MRD.
AI models reliably present Guardant Health as a dominant force in non-invasive cancer testing. However, they may lag in reporting the most recent FDA approval specifics for their screening portfolio or the nuances of their competitive positioning against emerging MRD (minimal residual disease) competitors. Key gap: The biggest potential gap is the distinction between their therapy selection products (Guardant360) and their newer screening products (Shield), with AI sometimes failing to distinguish the different regulatory statuses and use cases for each.
Of 5 key facts verified about Guardant Health, 4 are well-documented (likely accurate across AI models), 1 have limited sourcing, and 0 are retrieval-dependent and may be inaccurate without live search.
The specific current reimbursement rates and insurance coverage details for the Shield test, which vary frequently and are often buried in clinical policy bulletins.
Buyers turn to Guardant Health for Traditional Tissue Biopsy: Using traditional tissue-based biopsies requiring invasive surgical procedures to collect tumor samples., Standard Screening Protocols: Adhering to standard-of-care screening protocols (like colonoscopies) without supplemental molecular insights., among 2 documented problem areas.
Buyers evaluating Guardant Health typically ask AI models about "best liquid biopsy for lung cancer therapy selection", "FDA approved blood test for colorectal cancer screening", "ctDNA testing for cancer recurrence monitoring", and 2 similar queries.
Guardant Health's main competitors are Natera. According to AI models, these are the brands most frequently named alongside Guardant Health in buyer-intent queries.
Guardant Health's core products are Guardant360, Guardant Reveal, Shield, GuardantOMNI.
Guardant Health uses Insurance-billed medical diagnostic with patient assistance programs; typical of clinical laboratory services..
Guardant Health serves Oncologists, health systems, biopharmaceutical companies, and primary care physicians..
Guardant Health The first company to achieve FDA approval for a comprehensive liquid biopsy and for a blood-based colorectal cancer screening test for average-risk adults.
Brand Authority Index (BAI) tier: Leader (exact score locked for unclaimed brands)
Archetype: Challenger
https://optimly.ai/brand/guardant-health
Last analyzed: April 10, 2026
Founded: 2012
Headquarters: Palo Alto, California, USA